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Background: The impact of serum uric acid (SUA) on arteries of hypertensive subjects remains to be fully
established. This study investigated the relationship between SUA and carotid structural and hemodynamic
parameters in hypertensive men and women.
Methods: Three hundred and thirty eight patients (207 women and 131 men) were cross-sectionally evaluated by
clinical, laboratory, hemodynamic and carotid ultrasound analysis. Common carotid diameters, circumferential wall
tensions, Young’s Elastic Modulus, Stiffness Index, Arterial Compliance and intima-media thickness (IMT) were
determined. Internal carotid artery resistive index (ICRI), a hemodynamic measure that reflects local vascular
impedance and microangiopathy, was also assessed.
Results: Univariate analysis showed no significant correlation of SUA with carotid diameters, elasticity/stiffness
indexes, IMT and circumferential wall tensions in both genders. Conversely, SUA correlated with ICRI (r = 0.34;
p< 0.001) in women, but not in men, and hyperuricemic women presented higher ICRI than normouricemic ones
(0.684 ± 0.007 vs. 0.649 ± 0.004; p< 0.001). Stepwise and logistic regression analyses adjusted for potential
confounding factors showed that ICRI was independently associated with SUA and hyperuricemia in women.
Conclusions: This study demonstrated that SUA was associated with ICRI in hypertensive women, suggesting that
there might gender-related differences in the relationship between SUA and vascular damage in subjects with
systemic hypertension.
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Serum uric acid (SUA) has been considered an inde-
pendent predictor of cardiovascular events in hyperten-
sive patients [1]. Experimental data also showed that
uric acid stimulates proliferation, inflammation and oxida-
tive stress in vascular smooth-muscle cells, induces endo-
thelial dysfunction and activates the renin–angiotensin
system [1,2]. These observations have supported the
notion that SUA might be not only a marker but also a* Correspondence: wilnj@fcm.unicamp.br
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reproduction in any medium, provided the orcardiovascular risk factor [1,3]. Nevertheless, the im-
pact of SUA on the structure of large arteries of hyper-
tensive subjects remains controversial, since this variable
has been associated with subclinical atherosclerosis and
aortic stiffness in some hypertensive populations [4-6],
but not in others [7,8]. In this context, it can be specu-
lated that alternative mechanisms rather than remodel-
ing of large arteries could contribute to explain the
higher cardiovascular risk attributed to SUA in hyper-
tensive subjects. The resistive index of an artery is a
hemodynamic measure considered to reflect its vascular
impedance [9], and higher resistive index values consist
in a manifestation of local arteriolopathy [9,10]. Recent
data demonstrated an independent relationship between
SUA and renal artery resistive index in hypertensivetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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with microvascular damage and/or dysfunction in clin-
ical settings. However, the impact of SUA on the resist-
ive index of other arteries remains unknown.
In general, there has been no difference in the associ-
ation between SUA and cardiovascular risk in men and
women [1,2]. However, some reports suggested that
there might be gender-related differences in uric acid-
related adverse cardiovascular prognosis. Data from the
LIFE trial demonstrated that the association between the
level of SUA and cardiovascular outcomes was signifi-
cant only in women after adjustment for the Framing-
ham risk score [12]. In addition, SUA was found to be
independently associated with silent brain infarcts in
women, but not in men [13].
Aim
The present study investigated the relationship between
SUA and carotid hemodynamic and structural para-




Three hundred and thirty eight hypertensive subjects
(207 women and 131 men) were cross-sectionally evalu-
ated by clinical, laboratory, hemodynamic and carotid
ultrasound analysis. The subjects were randomly
selected from those attending an outpatient clinic of a
university hospital. Exclusion criteria were age under
18 years, neoplastic disease and identifiable causes of
secondary hypertension. The research was carried out in
accordance with the Declaration of Helsinki of the
World Medical Association. This study was approved by
the Human Research Ethics Committee of the State Uni-
versity of Campinas. All subjects gave written informed
consent to participate.
Clinical and laboratory data
Body mass index was calculated as body weight divided by
height squared (kg/m2). Waist circumference was mea-
sured at the midpoint between the lowest rib and the iliac
crest. Fasting blood total cholesterol, low-density-
lipoprotein cholesterol, high-density-lipoprotein choles-
terol, triglycerides, creatinine, glucose and C-reactive pro-
tein levels were measured using standard laboratory
techniques [14]. Creatinine clearance was estimated by the
Cockroft-Gault formula. SUA analysis was performed by
an enzymatic assay (Roche Diagnostics, Mannheim, Ger-
many). Definition of hyperuricemia was a SUA level
>7.0 mg/dL for men and >5.7 mg/dL for women [15].
Hypertension was defined as systolic blood pressure
≥140 mmHg or diastolic blood pressure ≥90 mmHg or
current antihypertensive medication use. Diabetesmellitus was diagnosed if fasting blood glucose was
≥126 mg/dL or when participants were taking
hypoglycemic medications, whereas metabolic syndrome
was defined in accordance with the National Cholesterol
Education Program Panel III criteria [16]. Women with
reported amenorrhea for more than 12 months, except
for pregnancy, were identified as postmenopausal.
Systemic hemodynamic data
Blood pressure and heart rate were measured using a
validated digital oscillometric device (HEM-705CP;
Omron Healthcare, Japan). Systolic volume was gener-
ated from Doppler interrogation of transaortic flow at
the aortic annular level and aortic cross-sectional area
using a Vivid 3 Pro apparatus (General Electric, USA)
equipped with a 2.5-MHz transducer [17]. Cardiac out-
put was calculated as systolic volume x cardiac fre-
quency, while peripheral vascular resistance was
obtained by the formula: mean blood pressure/cardiac
output.
Carotid analysis
Carotid ultrasonography was performed by a single
physician using a Vivid 3 Pro apparatus equipped with a
10-MHz linear-array transducer as previously described
[18]. A region 2 cm proximal to the carotid bifurcation
was identified, and the intima-media thickness (IMT) of
the far wall was evaluated as the distance between the
lumen–intima interface and the media–adventitia inter-
face. All measurements were made using an automatic
border recognizer (Vivid 3 Pro IMT software analyzer)
on still images obtained during the sonographic scan-
ning. End-diastolic and peak-systolic internal common
carotid artery diameters were obtained by continuous
tracing of 3 cycles and averaged. The ICRI was calcu-
lated as follows: 1–[minimum diastolic velocity/max-
imum systolic velocity] [9]. Common carotid artery
IMT and diameters as well ICRI were obtained as the
average from both right and left arteries measure-
ments. Carotid ultrasound and concomitant brachial
blood pressure measurements were used to calculate
Young’s Elastic Modulus, Artery Compliance and Stiff-
ness Index [19] and peak and mean circumferential
wall tension [20].
Young’s Elastic Modulus gives an estimate of arterial
stiffness that is independent of wall (intima-media)
thickness by the formula: ([systolic blood pressure – dia-
stolic blood pressure] x diastolic diameter)/([systolic
diameter – diastolic diameter]/IMT). Artery Compliance
measures the ability of the arteries to expand as a response
to pulse pressure caused by cardiac contraction and relax-
ation and was calculated as: ([systolic diameter – diastolic
diameter]/diastolic diameter)/(systolic blood pressure – dia-
stolic blood pressure). Stiffness Index is considered to be






Age, years 56.7 ± 0.9 59.1 ± 1.0
Body mass index, kg/m2 31.5 ± 0.4 29.8 ± 0.5†
Waist, cm 99.0 ± 1.0 102.3 ± 1.1*
Systolic blood pressure, mmHg 143.6 ± 1.7 140.8 ± 2.1
Diastolic blood pressure, mmHg 79.5 ± 1.2 76.6 ± 1.5
Pulse pressure, mmHg 64.1 ± 1.3 64.9 ± 1.6
Cardiac output, L/min 5.26 ± 0.09 5.73 ± 0.03†
Systemic vascular resistance, dynesseccm-5 1604 ± 30 1427± 34{
Metabolic syndrome, % 69 65
Diabetes mellitus, % 29 27
Smoking, % 6 14*
Menopause, % 75 ____
Previous stroke, % 7 11
Serum uric acid, mg/dL 5.4 ± 0.1 6.7 ± 0.2{
Creatinine, mg/dL 0.79 ± 0.02 1.12 ± 0.03†
Creatinine clearance, mL/min 99.0 ± 2.4 87.9 ± 3.0†
Low-density lipoprotein cholesterol, mg/dL 114.1 ± 2.5 103.5 ± 3.1†
High-density lipoprotein cholesterol, mg/dL 53.9 ± 1.2 46.8 ± 1.2{
Triglycerides, mg/dL 128 (92) 129 (101)
Fasting blood glucose, mg/dL 96 (29) 100 (28)
C-reactive protein, mg/dL 0.39 (0.66) 0.44 (0.40)*
Allopurinol, % 5 6
Diuretics, % 76 84
Beta-blockers, % 47 48
Calcium-channel-blockers, % 52 48
ACEI or ARB, % 80 85
Statins, % 20 24
Legend: ACEI or ARB – angiotensin-converting-enzyme inhibitors or
angiotensin-receptor blockers; *p< 0.05; †p< 0.01 and {p< 0.001 compared to
women.
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by the formula: (systolic blood pressure/diastolic blood
pressure)/([systolic diameter – diastolic diameter]/diastolic
diameter) [19].
Circumferential wall tension measurements were cal-
culated according to Laplace’s law: Peak circumferential
wall tension = systolic blood pressure x peak-systolic in-
ternal diameter/2; Mean circumferential wall tension =
mean blood pressure x ((systolic internal diameter + 2 x
diastolic internal diameter)/3)/2.
Intraobserver and interobserver carotid IMT and dia-
meters variabilities were <5%, while intraobserver and
interobserver variabilities of ICRI measurements were
<4%.
Statistical analysis
Continuous variables with and without normal distribu-
tion are presented as mean ± standard error and median
(25–75th percentile), respectively. The Kolmogorov–
Smirnov test was used to test for normal distribution of
the variables. χ2 was used to compare categorical vari-
ables whereas unpaired t-test and Mann–Whitney test
compared continuous variables with and without normal
distribution, respectively. Assessment of univariate cor-
relations between variables was examined using Pear-
son’s correlation coefficient for normally distributed data
and Spearman’s rank correlation coefficient for non-
normally distributed data. Fisher’s z-test was used to
compare correlation coefficients. Forward stepwise and
logistic regression analysis evaluated the independent
predictors of ICRI. Variables that exhibited significant
correlation coefficients (p< 0.05) with ICRI were
included as independent variables in stepwise regression
analysis, while variables that were statistically different
between hyperuricemic and normouricemic women were
included as independent variables in logistic regression
analysis. A p-value <0.05 was considered significant.
Results and Discussion
Clinical, hemodynamic and laboratory characteristics of
enrolled subjects are presented in Table 1, while carotid
features are shown in Table 2. Results of univariate ana-
lysis between SUA and carotid variables are presented in
Table 3. SUA exhibited no significant correlation with
common carotid artery diameters, Young’s Elastic
Modulus, Artery Compliance and Stiffness Index, IMT
and circumferential wall tension measurements in both
genders. Conversely, SUA correlated with ICRI (r = 0.34;
p< 0.001) in females but not in males (r =−0.11;
p= 0.19). The difference between these aforementioned
correlation coefficients was statistically significant (p
< 0.001) as assessed by Fisher’s z-test (Table 3). Further
univariate analysis demonstrated that ICRI also corre-
lated with pulse pressure (r = 0.44; p< 0.001), age(r = 0.38; p< 0.001), menopause status (r = 0.29; p
< 0.001), creatinine clearance (r =−0.27; p< 0.001), cre-
atinine (r = 0.23; p = 0.001), C-reactive protein (r = 0.22;
p= 0.003), body mass index (r = 0.19; p= 0.007) and
smoking (r = 0.15; p= 0.03) in women. SUA and ICRI
showed no significant relationship with systemic vascu-
lar resistance. Similarly, results of Spearman’s correlation
analysis revealed that carotid variables did not correlate
with use of any antihypertensive medication, statins or
allopurinol in both genders.
Clinical and carotid features of enrolled subjects were
then evaluated according to the presence or not of
hyperuricemia. No significant differences in carotid vari-
ables were detected between normouricemic and hyper-
uricemic men. On the other hand, hyperuricemic
Table 4 Clinical and carotid features of hypertensive
women according to the presence or not of
hyperuricemia
Variable Normouricemic Hyperuricemic P
(n = 131) (n = 76)
Serum uric acid, mg/dL 4.5 ± 0.1 6.9 ± 0.2 <0.001
Internal carotid resistive index 0.649± 0.004 0.684± 0.007 <0.001
Body mass index, kg/m2 30.3 ± 0.5 33.6 ± 0.7 <0.001
Creatinine, mg/dL 0.76 ± 0.01 0.86 ± 0.03 <0.001
Metabolic syndrome, % 62 82 0.004
Triglycerides, mg/dL 131.5 ± 5.9 157.8 ± 8.7 0.009
Age, years 55.2 ± 1.2 59.9 ± 1.4 0.01
Menopause, % 68 82 0.02
Waist circumference, cm 97.5 ± 1.3 102.1 ± 1.4 0.02
Legend. No other studied clinical or carotid variable was statistically different
between normouricemic and hyperuricemic women.






Intima-media thickness, mm 0.75 ± 0.01 0.79 ± 0.01*
Diastolic diameter, mm 5.4 ± 0.1 5.9 ± 0.1{
Systolic diameter, mm 6.1 ± 0.1 6.7 ± 0.1{
Young’s Elastic Modulus, mmHgmm 238± 8 270 ± 12*
Artery Compliance, %/10 mmHg 2.21 ± 0.07 2.28 ± 0.13
Stiffness Index 5.16 ± 0.18 4.97 ± 0.18
Peak CWT, 104 dynes/cm 5.9 ± 0.1 6.6 ± 0.1{
Mean CWT, 104 dynes/cm 3.8 ± 0.1 4.3 ± 0.1{
Internal carotid resistive index 0.662± 0.004 0.673 ± 0.005
Legend: CWT – circumferential wall tension. *p< 0.05 and {p< 0.001
compared to women.
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comparison to normouricemic ones, except for higher
ICRI, body mass index, age, creatinine and triglycerides
values and higher prevalence of metabolic syndrome and
menopause (Table 4).
Stepwise regression analysis was performed to evaluate
whether SUA was independently related to ICRI in
hypertensive women. A significant association between
ICRI and SUA was found in a model that also included
pulse pressure, age, C-reactive protein, body mass index,
smoking, creatinine clearance and menopause as inde-
pendent variables (Table 5). Forced inclusion of antihy-
pertensive classes, allopurinol and systemic vascular
resistance in this model did not change the results. Like-
wise, logistic regression analysis demonstrated that
ICRI ≥ 0.66 was independently associated with hyperuri-
cemia [Exp(B) (95%C.I.) = 3.35 (1.62–6.53); p< 0.001] inTable 3 Univariate analysis between serum uric acid and
common carotid artery features
Variable Female (n = 207) Male (n = 123) p (Z-test)
Intima-media thickness 0.10 0.01 0.42
Diastolic diameter 0.14 0.08 0.59
Systolic diameter 0.13 0.04 0.42
Young’s Elastic Modulus 0.14 −0.03 0.13
Artery Compliance −0.02 0.02 0.72










Legend: * p< 0.001. Z-test was used to compare correlation coefficients
between genders.a model that still included body mass index ≥ 30 kg/m2,
age> 55 years, triglycerides> 150 mg/dL, creatinine
clearance> 60 mL/min, menopause and metabolic syn-
drome as independent variables. On the other hand,
forced inclusion of antihypertensive classes and allopur-
inol in the logistic regression model did not change the
results.
Several lines of evidence demonstrated that SUA is an
independent predictor of worse cardiovascular outcomes
in hypertensive patients [1,3]. In addition, clinical studies
have indicated that SUA might be a risk factor for car-
diovascular diseases. In this regard, treatment with allo-
purinol not only lowered SUA levels but also reduced
blood pressure levels of adolescents with newly diag-
nosed essential hypertension [21], improved endothelial
dysfunction in subjects with chronic heart failure [22]
and slowed the progression of renal disease in patients
with chronic kidney disease [23]. In the present report,
we investigated the relationship between SUA and sev-
eral carotid hemodynamic and structural parameters in
a sample of hypertensive patients. Noticeably, SUA
exhibited an independent association with ICRI solely in
hypertensive women, but no relationship with carotidTable 5 Stepwise regression analysis for internal carotid
resistive index in hypertensive women
Variable R2 change P
Pulse pressure 0.221 <0.001
Serum uric acid 0.079 <0.001
Age 0.042 <0.001
C-reactive protein 0.019 0.02
Legend. The model also included body mass index, creatinine clearance,
smoking and menopause as independent variables. Creatinine was not
included in the regression model because of multicollinearity with creatinine
clearance. Further inclusion of antihypertensive classes, allopurinol and
systemic vascular resistance as independent variables did not change the
results.
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both genders. In addition, hyperuricemic subjects pre-
sented similar carotid parameters in comparison to nor-
mouricemic ones, except for higher ICRI values in
women. ICRI is a hemodynamic measure thought to re-
flect intracranial vascular impedance [9,24] and is a pre-
dictor of cardiovascular mortality and morbidity, at least
comparable to the well-established IMT [9,25]. It has
been assumed that increases in ICRI occur before the
thickening of the intima-media complex, consisting in a
manifestation of arteriolopathy in the territory irrigated
by the artery [9,10]. Thus, it can be speculated that SUA
was associated with intracranial microvascular damage
and/or dysfunction in hypertensive women. In agree-
ment with this assumption, data from a recent report
demonstrated that in a sample of women with high
prevalence of hypertension, SUA was related to silent
brain infarction [13], which may be considered a mani-
festation of cerebral microangiopathy.
The relationship between SUA and ICRI can be justified
by the ability of uric acid to induce vasoconstriction and
vascular remodeling. Uric acid is known to induce prolif-
eration and oxidative stress in cultured vascular smooth-
muscle cells, promote endothelial dysfunction and activate
the renin–angiotensin system [1,2]. Conversely, our data
from stepwise regression analysis revealed that ICRI was
not only related to SUA but also to C-reactive protein levels
in hypertensive women, indicating that inflammatory
mechanisms played a role in microvascular remodeling.
Interestingly, results of univariate analysis also revealed a
significant correlation between SUA and C-reactive protein
levels in hypertensive women (r =0.27; p< 0.001), a finding
that not only strengthens the idea that SUA is associated
with subclinical systemic inflammation in hypertensive sub-
jects [8], but also suggests that such association may con-
tribute to explain the relationship between SUA and ICRI
in our sample. In addition, the association between SUA
and ICRI was found to be independent of systemic vascular
resistance, indicating that selective arterial territories may
be sensitive to SUA.
It was very interesting that the increased level of SUA
was related to ICRI only in women. Generally speaking,
there has been no difference in the association between
SUA and cardiovascular risk in men and women [1-3], but
our results showed a clear difference between genders. In
this regard, a post hoc analysis of the LIFE trial indicated
that the association between the level of SUA and cardio-
vascular outcomes was significant only in women after ad-
justment for the Framingham risk score [12]. Likewise, data
from a population study revealed an association between
SUA and silent brain infarcts in women, but not in men
[13]. Moreover, SUA was shown to correlate to renal resist-
ive index only in women [11], strengthening the assump-
tion that this gender exhibits higher propensity to SUA-induced microvascular damage. A potential explanation for
such gender differences is not clear, but may include vari-
ation in sexual hormone profile. Menopause is associated
with increased SUA levels because of the uricosuric effect
of estrogen [26,27], which might have influenced our
results. However, the lack of impact of menopause status
on our regression analysis seems to weaken this assump-
tion. Therefore the exact underlying mechanisms should be
further investigated.
SUA was not related to carotid elasticity/stiffness indexes
and IMT in our sample. These findings agree with previous
studies showing no relationship between SUA and the
structure of large arteries in hypertensive subjects [7,8], but
are in contrast to data obtained in other hypertensive popu-
lations [4-6]. The reasons for such discrepancies are not ap-
parent, but it is possible that differences in clinical and
ethnical features among the studied populations played a
role in this regard. Furthermore, in many studies, aortic
stiffness, instead of carotid elastic properties, was studied
[4,5]. In this regard, it is possible that there might be differ-
ences in structural and functional features between these
two arteries [28]. On the other hand, we believe that the
lack of relationship was also explained by the high preva-
lence of metabolic syndrome in our sample, since SUA may
not be related to carotid structure among subjects with this
phenotype [29,30].
A potential limitation of our study was that its cross-
sectional design may limit our ability to infer a causal rela-
tionship between SUA and ICRI. Furthermore, it must be
acknowledged that the majority of patients were using anti-
hypertensive medications, which might be a confounding
factor in the analysis. In this regard, thiazide and loop
diuretics are known to increase SUA levels [31], while the
angiotensin receptor blocker losartan has unique uricosuric
properties [32]. In our sample, the use of thiazide or loop
diuretics was observed in 76% of women and 84% of men,
while losartan had been used by 14% of women and 7% of
men. Nevertheless, results of univariate analysis showed no
significant correlation between these aforementioned anti-
hypertensive medications and SUA levels in both genders
(data not shown). We also found that antihypertensive
medications exhibited no correlation with any studied ca-
rotid variable in both genders and forced inclusion of anti-
hypertensive medications in the regression models did not
change the association between SUA and ICRI in hyperten-
sive women.
Conclusions
The results of the present study demonstrated a previous
unknown association between SUA and ICRI solely in
hypertensive women. Further studies are warranted to
evaluate whether this association contributes to explain
uric acid-related adverse cardiovascular prognosis in
hypertensive subjects of this gender.
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